James D. Anderson

Array ( [id] => 13220491 [patent_doc_number] => 10124005 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-11-13 [patent_title] => Multisymptom migraine combination medication [patent_app_type] => utility [patent_app_number] => 15/844445 [patent_app_country] => US [patent_app_date] => 2017-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 763 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15844445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13457697 [patent_doc_number] => 20180280391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => NOVEL KIF5B-RET FUSION MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/839560 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15839560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14088627 [patent_doc_number] => 10240210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-26 [patent_title] => Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists [patent_app_type] => utility [patent_app_number] => 15/828719 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 23870 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15828719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311199 [patent_doc_number] => 20180207136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO [patent_app_type] => utility [patent_app_number] => 15/825505 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15825505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12259343 [patent_doc_number] => 20180078539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'T-CELL REGULATION IN T-CELL MEDIATED DISEASES BY REDUCING PATHOGENIC FUNCTION OF TH17 IN A HUMAN SUBJECT THROUGH TREATMENT WITH A NITROXIDE' [patent_app_type] => utility [patent_app_number] => 15/823321 [patent_app_country] => US [patent_app_date] => 2017-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25398 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15823321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14055301 [patent_doc_number] => 10231927 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-19 [patent_title] => Methotrexate composition [patent_app_type] => utility [patent_app_number] => 15/821242 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4258 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12675544 [patent_doc_number] => 20180117014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE [patent_app_type] => utility [patent_app_number] => 15/801482 [patent_app_country] => US [patent_app_date] => 2017-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15801482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18792598 [patent_doc_number] => 11826331 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-28 [patent_title] => Capric acid and myristic acid compositions for treating conditions [patent_app_type] => utility [patent_app_number] => 16/345880 [patent_app_country] => US [patent_app_date] => 2017-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 6509 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12183960 [patent_doc_number] => 20180042896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'USE OF AMISULPRIDE AS AN ANTI-EMETIC' [patent_app_type] => utility [patent_app_number] => 15/790481 [patent_app_country] => US [patent_app_date] => 2017-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3796 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15790481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16153633 [patent_doc_number] => 20200215049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => MAST CELL STABILIZERS FOR TREATMENT OF CHRONIC INFLAMMATORY CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/341277 [patent_app_country] => US [patent_app_date] => 2017-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177321 [patent_doc_number] => 20180036257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'ZEAXANTHIN FOR TUMOR TREATMENT' [patent_app_type] => utility [patent_app_number] => 15/784327 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5928 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15784327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649283 [patent_doc_number] => 20190231770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => COMBINATION COMPOSITIONS COMPRISING FXR AGONISTS FOR TREATING OR PREVENTING A FIBROTIC, CIRRHOTIC DISEASE OR DISORDER [patent_app_type] => utility [patent_app_number] => 16/339052 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13325765 [patent_doc_number] => 20180214420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent [patent_app_type] => utility [patent_app_number] => 15/722399 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15722399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12183933 [patent_doc_number] => 20180042869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'THERAPEUTIC AGENTS FOR USE IN THE PROPYLAXIS AND/OR TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/713372 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5856 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15713372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15306347 [patent_doc_number] => 10517854 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Dosing regiments of celgosivir for the treatment of dengue [patent_app_type] => utility [patent_app_number] => 15/706845 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 15302 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15706845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572119 [patent_doc_number] => 10894030 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells [patent_app_type] => utility [patent_app_number] => 15/703165 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8242 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15703165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717071 [patent_doc_number] => 20170369490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/700351 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15700351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14015105 [patent_doc_number] => 20190069546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => BUFFERED SILVER COMPLEX BIOCIDE [patent_app_type] => utility [patent_app_number] => 15/697765 [patent_app_country] => US [patent_app_date] => 2017-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15697765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702076 [patent_doc_number] => 20180125858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => BIOAVAILABLE SOLID STATE (17- β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS [patent_app_type] => utility [patent_app_number] => 15/672185 [patent_app_country] => US [patent_app_date] => 2017-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15672185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117235 [patent_doc_number] => 20180000822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 15/650459 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 7492 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650459 [rel_patent_id] =>[rel_patent_doc_number] =>)